[Effects of mycophenolate mofetil in ischemic acute renal failure in rats]

M Chávez-Velásquez1, H Pons, M Medina

  • 1Centro de Medicina y Cirugía Experimental, Facultad de Medicina, Universidad del Zulia, Unidad de Diálisis y Trasplante Renal Hospital Universitario de Maracaibo, Venezuela. Mard18@hotmail.com

Insights

Mycophenolate mofetil (MMF) administered before renal ischemia reduced kidney damage and cellular infiltration. Pre-treatment with MMF improved outcomes compared to post-treatment or no treatment, suggesting a protective effect against ischemia reperfusion injury.

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Kidney grafts are susceptible to ischemia reperfusion injury (IRI) due to cold ischemia.
  • Early cellular infiltration contributes to IRI severity.
  • Mycophenolate mofetil (MMF) is an immunosuppressant that inhibits purine synthesis.

Purpose of the Study:

  • To investigate the effect of MMF timing on IRI in a rat model.
  • To determine if inhibiting early cellular infiltration impacts IRI severity.

Main Methods:

  • 45 rats underwent renal artery clamping and contralateral nephrectomy.
  • MMF was administered either 2 days before (pre-MMF) or after (post-MMF) ischemia, or vehicle (control).
  • Serum creatinine, kidney histology, and cellular infiltration (T-lymphocytes, monocytes) were assessed.

Main Results:

  • Pre-MMF group showed significantly lower serum creatinine on post-ischemic day 2 compared to post-MMF and control groups.
  • Histologic damage was lower in the pre-MMF group than the post-MMF group on day 2.
  • While MMF reduced T-lymphocyte and monocyte infiltration on day 2, tubulointerstitial necrosis was more severe in MMF-treated groups by day 5.

Conclusions:

  • Pre-treatment with MMF may mitigate histologic damage from renal IRI.
  • The timing of MMF administration is critical in managing IRI.
  • Further research is needed to understand the long-term effects and mechanisms of MMF in IRI.